HUE047910T2 - Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal - Google Patents

Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal

Info

Publication number
HUE047910T2
HUE047910T2 HUE14802544A HUE14802544A HUE047910T2 HU E047910 T2 HUE047910 T2 HU E047910T2 HU E14802544 A HUE14802544 A HU E14802544A HU E14802544 A HUE14802544 A HU E14802544A HU E047910 T2 HUE047910 T2 HU E047910T2
Authority
HU
Hungary
Prior art keywords
eye
treating conditions
vegf darpin
darpin
vegf
Prior art date
Application number
HUE14802544A
Other languages
English (en)
Inventor
Thomas Hohman
Janet Cheetham
Scott Whitcup
Erik Lippa
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of HUE047910T2 publication Critical patent/HUE047910T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HUE14802544A 2013-11-05 2014-11-04 Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal HUE047910T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361900246P 2013-11-05 2013-11-05
US201462016620P 2014-06-24 2014-06-24

Publications (1)

Publication Number Publication Date
HUE047910T2 true HUE047910T2 (hu) 2020-05-28

Family

ID=51947485

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14802544A HUE047910T2 (hu) 2013-11-05 2014-11-04 Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal

Country Status (14)

Country Link
US (4) US20150126458A1 (hu)
EP (2) EP3065761B1 (hu)
JP (3) JP2016536369A (hu)
KR (1) KR20160070164A (hu)
CN (1) CN105960247A (hu)
AU (2) AU2014346921A1 (hu)
CA (1) CA2927012A1 (hu)
DK (1) DK3065761T3 (hu)
ES (1) ES2773317T3 (hu)
HU (1) HUE047910T2 (hu)
PL (1) PL3065761T3 (hu)
PT (1) PT3065761T (hu)
TW (1) TWI729970B (hu)
WO (1) WO2015069668A1 (hu)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ571300A (en) 2006-04-07 2011-12-22 Warner Chilcott Co Llc Antibodies that bind human protein tyrosine phosphatase beta (HPTPBeta) and uses thereof
CN104039351A (zh) 2011-10-13 2014-09-10 阿尔皮奥治疗学股份有限公司 用于治疗血管渗漏综合征和癌症的方法
EP2846836B1 (en) 2012-05-07 2019-08-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy
CA3099551A1 (en) 2018-05-10 2019-11-14 Regeneron Pharmaceuticals, Inc. High concentration vegf receptor fusion protein containing formulations
US10894824B2 (en) 2018-09-24 2021-01-19 Aerpio Pharmaceuticals, Inc. Multispecific antibodies that target HPTP-β (VE-PTP) and VEGF
EP3980045A1 (en) * 2019-06-04 2022-04-13 Molecular Partners AG Recombinant fap binding proteins and their use
IL301762A (en) * 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases
CN114075290B (zh) * 2022-01-20 2022-04-19 南京鼓楼医院 Cd40靶向结合蛋白、其编码核酸以及用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MEP3208A (xx) 1999-06-08 2010-02-10 Regeneron Pharma Modifikovani himerni polipeptidi sa poboljšanim farmakokinetičkim osobinama
WO2002020565A2 (en) 2000-09-08 2002-03-14 Universität Zürich Collections of repeat proteins comprising repeat modules
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
EP1996937A4 (en) 2006-03-06 2009-04-08 Amunix Inc GENETIC PACKS AND USES THEREOF
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
DK2369005T3 (da) 2007-06-21 2013-06-24 Univ Muenchen Tech Biologisk aktive proteiner med forøget stabilitet in vivo og/eller in vitro
RU2550258C2 (ru) * 2008-11-03 2015-05-10 Молекьюлар Партнерс Аг Связывающие белки, ингибирующие взаимодействия vegf-a рецептора
TWI510246B (zh) * 2010-04-30 2015-12-01 Molecular Partners Ag 抑制vegf-a受體交互作用的經修飾結合性蛋白質
EP2846836B1 (en) * 2012-05-07 2019-08-14 Allergan, Inc. Method of treating amd in patients refractory to anti-vegf therapy

Also Published As

Publication number Publication date
CN105960247A (zh) 2016-09-21
JP2022107628A (ja) 2022-07-22
ES2773317T3 (es) 2020-07-10
TWI729970B (zh) 2021-06-11
DK3065761T3 (da) 2020-02-17
TW201609125A (zh) 2016-03-16
AU2014346921A1 (en) 2016-06-02
JP2020169191A (ja) 2020-10-15
US20170157207A1 (en) 2017-06-08
EP3065761B1 (en) 2020-01-08
US20210008158A1 (en) 2021-01-14
JP2016536369A (ja) 2016-11-24
WO2015069668A1 (en) 2015-05-14
US20220175881A1 (en) 2022-06-09
PL3065761T3 (pl) 2020-05-18
EP3065761A1 (en) 2016-09-14
EP3628324A1 (en) 2020-04-01
CA2927012A1 (en) 2015-05-14
AU2020202968A1 (en) 2020-05-21
PT3065761T (pt) 2020-02-21
KR20160070164A (ko) 2016-06-17
US20150126458A1 (en) 2015-05-07

Similar Documents

Publication Publication Date Title
IL286808A (en) System and methods for ocular injection
IL278018A (en) Methods for the treatment or prevention of ophthalmological conditions
HK1222791A1 (zh) 用於眼睛的光線療法的裝置
HK1225654A1 (zh) 用於治療老花眼的組合物及方法
HK1217908A1 (zh) 治療膽管癌的方法
DK3057993T3 (en) Method for Treating Conditions Associated with MASP-2 Dependent Complement
HK1248552A1 (zh) 使用川地匹坦的治療方法
HUE047910T2 (hu) Eljárás a szem állapotainak kezelésére anti-VEGF darpinnal
HK1232235A1 (zh) 治療和診斷過表達α- -β- 的癌症的方法
EP2971944A4 (en) MULTI-LENS MONOBLOC OPTICAL ELEMENT AND METHOD OF MANUFACTURE
SI3027564T1 (sl) Talilnik in postopek za zakrito zgorevanje
EP2945639A4 (en) METHOD FOR THE TREATMENT OF HEART DISEASES
IL251769A0 (en) Methods for treating eye conditions
EP3079679A4 (en) Method of treatment of alopecia with monoterpenoids
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
GB201501315D0 (en) Submerged combustion melters and methods
GB201421861D0 (en) Method of aquiring fuel injector characteristics
SG10201802808SA (en) Method of treating ocular disorders
GB201317835D0 (en) Bottle and method for the introduction of an additive into a central heating radiator
EP2959018A4 (en) METHODS OF EVALUATION OF THE DEVELOPMENT RISK OF CANINE ATOPIC DERMATITIS